Research Triangle Park, NC, United States of America

Paul L Feldman


Average Co-Inventor Count = 6.0

ph-index = 5

Forward Citations = 125(Granted Patents)


Location History:

  • Durham, NC (US) (2007)
  • Research Triangle Park, NC (US) (2008 - 2009)

Company Filing History:


Years Active: 2007-2009

Loading Chart...
5 patents (USPTO):Explore Patents

Title: Paul L Feldman: Innovator in Short-Acting Benzodiazepines

Introduction

Paul L Feldman is a notable inventor based in Research Triangle Park, NC (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of short-acting benzodiazepines. With a total of 5 patents to his name, Feldman continues to push the boundaries of medical innovation.

Latest Patents

Feldman's latest patents focus on the formulation of short-acting benzodiazepines. These compounds, described in his patents, contain a carboxylic ester moiety that allows for inactivation by nonspecific tissue esterases. This mechanism provides a more predictable and reproducible pharmacodynamic profile. The compounds are suitable for various therapeutic purposes, including sedative-hypnotic, anxiolytic, muscle relaxant, and anticonvulsant applications. They are particularly useful in clinical settings such as preoperative sedation, conscious sedation during diagnostic procedures, and ICU sedation.

Career Highlights

Feldman is currently associated with Cenes Limited, where he applies his expertise in pharmaceutical innovation. His work has been instrumental in advancing the understanding and application of benzodiazepine derivatives in medical practice.

Collaborations

Feldman has collaborated with notable colleagues, including David Kendall Jung and Istvan Kaldor. These partnerships have contributed to the successful development of his patented compounds.

Conclusion

Paul L Feldman is a distinguished inventor whose work in short-acting benzodiazepines has the potential to enhance therapeutic practices in medicine. His innovative contributions continue to shape the landscape of pharmaceutical development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…